Oncoinvent ASA: Notice of Extraordinary General Meeting

03 Jul 2025 15:45 CEST

An extraordinary general meeting in Oncoinvent ASA will be held on 4. August
2025 at  12:00

CEST. The meeting will be held in Gullhaugveien 7, Oslo with the possibility for
a virtual participation. The formal call will be sent to all shareholders
registered in the Norwegian Central Security Depository (VPS). The complete set
of documents and link relating to the extraordinary general meeting will be made
available on www.oncoinvent.com/investors/general-meetings.

Shareholders are recommended to exercise their shareholder rights through
completing the proxy form with voting instruction.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. Currently two phase 1/2a trials and one
randomized phase 2 trial are ongoing in the US, UK and Europe. Preliminary
clinical efficacy data are highly encouraging, and no serious toxicity or safety
concerns have been reported to date. The Oncoinvent team consists of approx. 30
employees and runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the
Euronext Growth Oslo.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of billions of
calcium carbonate microparticles containing the radioactive material radium-224.
The mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in ongoing
clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal
cancer and it is administered intraperitoneally after surgical resection with
removal of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.

For further information, please contact:

Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

More information:
Access the news on Oslo Bors NewsWeb site

650680_Oncoinvent_ASA_Notice_of_EGM_4_August_2025_vF.pdf